Anteris Technologies' (ASX:AVR) subsidiary, Anteris Technologies Global Corp. (ATGC), launched the roadshow for its proposed initial public offering of 14.8 million common shares in the US, according to a Tuesday filing with the Australian bourse.
ATGC applied to list its common stock on the Nasdaq Global Market under the ticker symbol "AVR." The unit intends to grant the underwriters a 30-day option to purchase up to an additional 2.2 million shares at the IPO price, less underwriting discounts and commissions, the filing stated.
Following the offering, ATGC intends to list its CHESS Depositary Interests on the Australian Securities Exchange under the same symbol.
Proceeds will be used to fund the ongoing development of Anteris' DurAVR transcatheter heart valve.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.